Aphria has received its EU GMP certification from the Malta Medicines Authority at its facility in Leamington, Ontario.
Aphria (TSX:APHA,NYSE:APHA) has received its European Union Good Manufacturing Practices (EU GMP) certification as an active substance manufacturer from the Malta Medicines Authority (MMA) at its Aphria One facility in Leamington, Ontario.
As quoted in the press release:
This marks Aphria’s second EU GMP certified facility, following the previously announced certification at the Company’s subsidiary, ARA – Avanti Rx Analytics (“Avanti”).
“We are pleased to receive EU GMP certification for our Aphria One facility which strengthens our international export capabilities,” said Irwin D. Simon, Chief Executive Officer. “Looking ahead, we are excited by the momentum and expect to see acceleration in terms of both sales and profitability in the second half of fiscal 2020. We continue to believe the opportunities for long-term shareholder value creation are very strong in Canada and internationally.”